Details of the Drug Combinations

General Information of This Drug (ID: DMH5MVE)

Drug Name

Sodium stibogluconate DMH5MVE

Synonyms

Lenocta; Sodium stibogluconate (cancer); VQD-001; Sodium stibogluconate (cancer), Greenwich; Sodium stibogluconate (cancer), VioQuest

Indication

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Approved	[1]
Leishmaniasis	1F54	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Sodium stibogluconate + Interferon alfa-2B	DCX1HFP	Interferon alfa-2B	Advanced Cancer	[4]
Paromomycin + Sodium stibogluconate	DCCNH33	Paromomycin	Visceral Leishmaniasis	[5]
------------------------------------------------------------------------------------

References

1	Perspectives of antimony compounds in oncology. Acta Pharmacol Sin. 2008 Aug;29(8):881-90.
2	Leishmaniasis in Norway. Tidsskr Nor Laegeforen. 2021 Feb 22;141(3).
3	Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents. J Parasitol. 2004 Oct;90(5):1155-62.
4	ClinicalTrials.gov (NCT00629200) Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
5	ClinicalTrials.gov (NCT03129646) Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa